Malick M Gibani
Overview
Explore the profile of Malick M Gibani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
881
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kavallieros K, Baltas I, Konstantinou G, Koutoumanou E, Gibani M, Gilchrist M, et al.
J Med Microbiol
. 2024 Jun;
73(6).
PMID: 38922673
Fluoroquinolone prophylaxis during haematopoietic cell transplantation (HCT) can lead to antimicrobial resistance (AMR). Identifying the groups of patients that have the highest likelihood of benefiting from prophylactic antimicrobials is important...
2.
Baltas I, Kavallieros K, Konstantinou G, Koutoumanou E, Gibani M, Gilchrist M, et al.
JAC Antimicrob Resist
. 2024 Feb;
6(1):dlae010.
PMID: 38304723
Objectives: Fluroquinolone prophylaxis during haematopoietic cell transplantation (HCT) remains contentious. We aimed to determine its effectiveness and association with exposure to treatment antimicrobials and antimicrobial resistance. Methods: All admission episodes...
3.
Smith C, Smith E, Rydlova A, Varro R, Hinton J, Gordon M, et al.
BMJ Open
. 2024 Jan;
14(1):e076477.
PMID: 38199617
Introduction: Invasive non-typhoidal (iNTS) serovars are a major cause of community-acquired bloodstream infections in sub-Saharan Africa (SSA). In this setting, serovar Typhimurium accounts for two-thirds of infections and is associated...
4.
Smith C, Smith E, Chiu C, Hinton J, Perez Sepulveda B, Gordon M, et al.
Wellcome Open Res
. 2023 Oct;
8:111.
PMID: 37808389
Invasive non-typhoidal disease (iNTS) is a major cause of morbidity and mortality globally, particularly as a cause of bloodstream infection in children and immunocompromised adults in sub-Saharan Africa. Vaccines to...
5.
Barton A, Hill J, OConnor D, Jones C, Jones E, Camara S, et al.
Infect Immun
. 2023 Sep;
91(10):e0010823.
PMID: 37725060
Enteric fever, caused by oral infection with typhoidal serovars, presents as a non-specific febrile illness preceded by an incubation period of 5 days or more. The enteric fever human challenge...
6.
Baltas I, Gilchrist M, Koutoumanou E, Gibani M, Meiring J, Otu A, et al.
JAC Antimicrob Resist
. 2023 Aug;
5(4):dlad091.
PMID: 37533762
Objectives: A novel 'subscription-type' funding model was launched in England in July 2022 for ceftazidime/avibactam and cefiderocol. We explored the views of infection consultants on important aspects of the delinked...
7.
Zhu H, Chelysheva I, Cross D, Blackwell L, Jin C, Gibani M, et al.
J Clin Invest
. 2023 Jul;
133(16).
PMID: 37402153
BACKGROUNDTyphoid fever is caused by the Gram-negative bacterium Salmonella enterica serovar Typhi and poses a substantial public health burden worldwide. Vaccines have been developed based on the surface Vi-capsular polysaccharide...
8.
Rimmer S, Barnacle J, Gibani M, Wu M, Dissanayake O, Mehta R, et al.
Int J Infect Dis
. 2022 Nov;
126:48-53.
PMID: 36410691
Objectives: Since May 2022, cases of human monkeypox virus (hMPXV) with human-to-human cross-transmission have significantly increased in nonendemic countries. Our aim was to characterize diagnostic features of patients with confirmed...
9.
Carey M, McCann N, Gibani M
Curr Opin Infect Dis
. 2022 Aug;
35(5):424-430.
PMID: 35984009
Purpose Of Review: Momentum for achieving widespread control of typhoid fever has been growing over the past decade. Typhoid conjugate vaccines represent a potentially effective tool to reduce the burden...
10.
Davies J, Gibani M, Portone G, McGregor A
J Infect
. 2022 Apr;
85(1):e18-e20.
PMID: 35427720
No abstract available.